BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28322465)

  • 1. Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
    Yéléhé-Okouma M; Martini H; Lemarié J; Labroca P; Petitpain N; Gibaja V; Paille F; Gillet P
    Fundam Clin Pharmacol; 2017 Oct; 31(5):574-579. PubMed ID: 28322465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe opioid withdrawal syndrome after a single dose of nalmefene.
    Donnerstag N; Schneider T; Lüthi A; Taegtmeyer A; Raetz Bravo A; Mehlig A
    Eur J Clin Pharmacol; 2015 Aug; 71(8):1025-6. PubMed ID: 26050241
    [No Abstract]   [Full Text] [Related]  

  • 3. Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
    Pélissier F; Rougé Bugat ME; Nubukpo P; Franchitto N
    J Clin Psychopharmacol; 2016 Feb; 36(1):100-3. PubMed ID: 26658085
    [No Abstract]   [Full Text] [Related]  

  • 4. [Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
    Dahmke H; Kupferschmidt H; Kullak-Ublick GA; Weiler S
    Praxis (Bern 1994); 2015 Oct; 104(21):1129-34. PubMed ID: 26463904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.
    Franchitto N; Jullian B; Salles J; Pelissier F; Rolland B
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):669-677. PubMed ID: 28343423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M; Friede M; Schnitker J
    Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
    Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
    Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
    Soyka M
    Expert Opin Pharmacother; 2016; 17(4):619-26. PubMed ID: 26810044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy for Substance Use Disorders.
    Klein JW
    Med Clin North Am; 2016 Jul; 100(4):891-910. PubMed ID: 27235620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Illogical association nalmefene and opioids: Analysis in the French pharmacovigilance database].
    Favrelière S; Lafay-Chebassier C; Fauconneau B; Quillet A; Yéléhé-Okouma M; Montastruc F; Pérault-Pochat MC
    Therapie; 2019 Jun; 74(3):369-374. PubMed ID: 30197228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nalmefene for the treatment of alcohol dependence: a current update.
    Soyka M
    Int J Neuropsychopharmacol; 2014 Apr; 17(4):675-84. PubMed ID: 24246244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nalmefene for elective reversal of procedural sedation in children.
    Chumpa A; Kaplan RL; Burns MM; Shannon MW
    Am J Emerg Med; 2001 Nov; 19(7):545-8. PubMed ID: 11698998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine.
    Lescut C; Gaboriau L; Carton L; Rolland B
    J Clin Psychopharmacol; 2017 Oct; 37(5):631-633. PubMed ID: 28806388
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
    Ward HB; Barnett BS; Suzuki J
    Subst Abus; 2019; 40(2):140-145. PubMed ID: 30888254
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of nalmefene glucuronide as a selective gut opioid antagonist.
    Cheskin LJ; Chami TN; Johnson RE; Jaffe JH
    Drug Alcohol Depend; 1995 Aug; 39(2):151-4. PubMed ID: 8529534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
    Gual A; He Y; Torup L; van den Brink W; Mann K;
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.
    Mann K; Torup L; Sørensen P; Gual A; Swift R; Walker B; van den Brink W
    Eur Neuropsychopharmacol; 2016 Dec; 26(12):1941-1949. PubMed ID: 27842940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
    Mason BJ; Salvato FR; Williams LD; Ritvo EC; Cutler RB
    Arch Gen Psychiatry; 1999 Aug; 56(8):719-24. PubMed ID: 10435606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.